Yes. But, you must be certified for treatment by a Mississippi Department of Health (MDOH) credentialed medical cannabis practitioner. The Mississippi Medical Cannabis Act allows patients to be certified for medical marijuana treatment if they have a “debilitating medical condition”, which includes the following:
Cancer, Parkinson’s disease, Huntington’s disease, muscular dystrophy, glaucoma, spastic quadriplegia, positive status for human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, amyotrophic lateral sclerosis (ALS), Crohn’s disease, ulcerative colitis, sickle-cell anemia, Alzheimer’s disease, agitation of dementia, post-traumatic stress disorder (PTSD), autism, pain refractory to appropriate opioid management, diabetic/peripheral neuropathy, spinal cord disease or severe injury, or the treatment of these conditions Section 2 of The Mississippi Medical Marijuana Act:
The MDOH hopes to begin credentialing physicians no later than June 3rd, 2022. A list of credentialed doctors will be available then. After being certified you will then apply for your medical cannabis identification card through the Mississippi Department of Health. Products may not be available for purchase until late fall 2022.
Mississippi’s medical cannabis laws allow only MDOH credentialed practitioners to prescribe medical cannabis.
Marijuana strains vary in their amounts of THC or CBD. By state law, the flower cannot contain more than 30% THC, and all other forms are not more than 60% THC.
And, as with any medication, there are risks and side effects to consider. That is why it is so important to talk to your MDOH credentialed medical cannabis practitioner, pharmacist, and medical cannabis dispensary agent to help you consider:
The use of medical cannabis in the treatment of sickle cell anemia is demonstrated to be safe and potentially effective, especially in side effects such as chronic and debilitating pain. This type of pain is among the most frequent side effects among patients and can remain present throughout a patient’s life. Currently, very few options exist for patients in treating the symptoms associated with sickle cell. Opioids are the most commonly used form of medication. Generally, opioids are being prescribed less frequently in treatment for sickle cell, in which patients are left with few choices. Nationally, demand has increased for medical cannabis as a form of treatment in the fight against sickle cell anemia.
Disclaimer: The content reported here is intended to provide the public with information as reported by medical and scientific studies and data available to the Mississippi Cannabis Patients Alliance. The Alliance does not provide a diagnosis of patient conditions or provide healthcare recommendations for a specific patient. All patients should consult their healthcare provider on any forms of treatment specific to their current condition.
Research in the use of medical cannabis to treat sickle cell anemia is ongoing, and many studies have illustrated positive results. The most commonly studied use of medical cannabis is in the impact on chronic pain. Among many studies, one of the most common factors is that medical cannabis has the ability to play a longer-term role in pain treatment and that its use becomes more effective over time. Additionally, as medical cannabis treatment continues, patients are more likely to be able to enjoy more energy, increase physical activity, sleep better, and have better impacts on their mental health.
As more states legalize medical cannabis for patients, research has indicated that more patients are experiencing decreased severity and a decrease in hospitalizations due to ongoing side effects. While most researchers conclude that all treatment options for sickle cell anemia are difficult due to the nature of the disease, and therefore make pain management challenges for all patients. Most thus far have determined that in a majority of patients in clinical studies, medical cannabis over opioids has offered the most beneficial and consistent outcomes in the longer term.